Sillajen
Scope
Date
~
-
Bio & PharmaSillaJen: First to use lab-grown human tissue to find best cancer drug dose
South Korean biotechnology firm SillaJen Inc. is pioneering a new approach to determine the best dose for a cancer drug combination in clinical tria...
Mar 18, 2025 (Gmt+09:00)
-
Bio & PharmaSillaJen starts US trial of anti-cancer drug from Basilea
SillaJen Inc. said on Monday it has enrolled the first patient in a US phase 1 trial of an anti-cancer drug BAL0891 licensed from Swiss drugmaker Ba...
Feb 27, 2023 (Gmt+09:00)
-
Corporate restructuringM2N to sell 52% stake in Chinese automotive parts company DKCA
M2N( DK D&I Co. ), the parent company of pharmaceutical firm Sillajen Inc., announced on Tuesday that it has signed an agreement to sell its maj...
Dec 28, 2022 (Gmt+09:00)
-
Bio & PharmaS. Korea's SillaJen launches clinical trials in US for new anti-cancer drug
South Korean biotech company Sillajen Inc. has started recruiting patients for Phase 1 clinical trials in the US for an anti-cancer drug from a Swis...
Dec 14, 2022 (Gmt+09:00)
-
Bio & PharmaSillaJen shares jump as exchange maintains listing, allows resumed trade
Shares in South Korea’s scandal-hit biotechnological company SillaJen Inc. soared on Thursday after the local exchange decided to maintain the...
Oct 13, 2022 (Gmt+09:00)
-
Fraud scandalsScandal-hit SillaJen faces higher delisting risk
South Korea's SillaJen Inc., once the largest stock on Kosdaq by market value, faces a higher risk of being kicked out of the country's junior stock...
Jan 19, 2022 (Gmt+09:00)
Latest News
- 1 BMW Surpasses Mercedes in Sales – Imported Car Market 'Shake-Up'
- 2 Seoul appeal: Korean art captivates Indonesia’s affluent connoisseurs
- 3 CJ CheilJedang scraps $3.5 bn green bio sale, shifts gears to expansion
- 4 Trump Jr. meets Korean business chiefs in back-to-back sessions
- 5 Samsung in talks to supply customized HBM4 to Nvidia, Broadcom, Google
